Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Kathy Gately"'
Autor:
Cathy E. Richards, Yasir Y. Elamin, Aoife Carr, Kathy Gately, Shereen Rafee, Mattia Cremona, Emer Hanrahan, Robert Smyth, Daniel Ryan, Ross K. Morgan, Susan Kennedy, Lance Hudson, Joanna Fay, Kenneth O’Byrne, Bryan T. Hennessy, Sinead Toomey
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 13, p 10545 (2023)
PTPN11 encodes the SHP2 protein tyrosine phosphatase that activates the mitogen-activated protein kinase (MAPK) pathway upstream of KRAS and MEK. PTPN11/Shp2 somatic mutations occur frequently in Juvenile myelomonocytic leukaemia (JMML); however, the
Externí odkaz:
https://doaj.org/article/6dfb1fbd27d14df4ba344828c1f6dcc5
Publikováno v:
Cancers, Vol 15, Iss 6, p 1635 (2023)
Activating mutations in KRAS are highly prevalent in solid tumours and are frequently found in 35% of lung, 45% of colorectal, and up to 90% of pancreatic cancers. Mutated KRAS is a prognostic factor for disease-free survival (DFS) and overall surviv
Externí odkaz:
https://doaj.org/article/f262837402ef49b8a213a9ef84da7f7e
Autor:
Sinead Toomey, Aoife Carr, Mateusz Janusz Mezynski, Yasir Elamin, Shereen Rafee, Mattia Cremona, Clare Morgan, Stephen Madden, Khairun I. Abdul-Jalil, Kathy Gately, Angela Farrelly, Elaine W. Kay, Susan Kennedy, Kenneth O’Byrne, Liam Grogan, Oscar Breathnach, Patrick G. Morris, Alexander J. Eustace, Joanna Fay, Robert Cummins, Anthony O’Grady, Roshni Kalachand, Norma O’Donovan, Fergal Kelleher, Aine O’Reilly, Mark Doherty, John Crown, Bryan T. Hennessy
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-14 (2020)
Abstract Background An increasing number of anti-cancer therapeutic agents target specific mutant proteins that are expressed by many different tumor types. Successful use of these therapies is dependent on the presence or absence of somatic mutation
Externí odkaz:
https://doaj.org/article/b0a3ce4f632e46aeb43bc18b4d3e61a7
Autor:
Susan Heavey, Paul Dowling, Gillian Moore, Martin P. Barr, Niamh Kelly, Stephen G. Maher, Sinead Cuffe, Stephen P. Finn, Kenneth J. O’Byrne, Kathy Gately
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-12 (2018)
Abstract The PI3K-mTOR pathway is involved in regulating all hallmarks of cancer, and is often dysregulated in NSCLC, making it an attractive therapeutic target in this setting. Acquired resistance to PI3K-mTOR inhibition is a major hurdle to overcom
Externí odkaz:
https://doaj.org/article/a8ae152a78804d6da7975d71e4a44b98
Autor:
Gillian Moore, Clara Lightner, Samira Elbai, Lauren Brady, Siobhan Nicholson, Ronan Ryan, Katie E. O’Sullivan, Kenneth J. O’Byrne, Carmen Blanco-Aparicio, Sinead Cuffe, Michael O’Neill, Susan Heavey, Stephen P. Finn, Kathy Gately
Publikováno v:
Cancers, Vol 13, Iss 9, p 2139 (2021)
PIM kinases are constitutively active proto-oncogenic serine/threonine kinases that play a role in cell cycle progression, metabolism, inflammation and drug resistance. PIM kinases interact with and stabilize p53, c-Myc and parallel signaling pathway
Externí odkaz:
https://doaj.org/article/1d73af4dcbaa4b6291be07d7d9eeb0dd
Autor:
Martin P. Barr, Steven G. Gray, Kathy Gately, Emily Hams, Padraic G. Fallon, Anthony Mitchell Davies, Derek J. Richard, Graham P. Pidgeon, Kenneth J. O’Byrne
Publikováno v:
Molecular Cancer, Vol 19, Iss 1, Pp 1-2 (2020)
Since the publication of this work [1] and in response to a recent query that was brought to our attention in relation to the Western Blot in Figure 1(C) for NP2, protein lysates prepared around the same time as those presented in the manuscript in q
Externí odkaz:
https://doaj.org/article/056d4139098d453fb0b44b335d126544
Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells
Autor:
Patricia Gaule, Nupur Mukherjee, Brendan Corkery, Alex J. Eustace, Kathy Gately, Sandra Roche, Robert O’Connor, Kenneth J. O’Byrne, Naomi Walsh, Michael J. Duffy, John Crown, Norma O’Donovan
Publikováno v:
Cancers, Vol 11, Iss 4, p 548 (2019)
In pre-clinical studies, triple-negative breast cancer (TNBC) cells have demonstrated sensitivity to the multi-targeted kinase inhibitor dasatinib; however, clinical trials with single-agent dasatinib showed limited efficacy in unselected populations
Externí odkaz:
https://doaj.org/article/e16a74b79fd843269694366529e91d6b
Autor:
Toomey, Cathy E. Richards, Yasir Y. Elamin, Aoife Carr, Kathy Gately, Shereen Rafee, Mattia Cremona, Emer Hanrahan, Robert Smyth, Daniel Ryan, Ross K. Morgan, Susan Kennedy, Lance Hudson, Joanna Fay, Kenneth O’Byrne, Bryan T. Hennessy, Sinead
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 13; Pages: 10545
PTPN11 encodes the SHP2 protein tyrosine phosphatase that activates the mitogen-activated protein kinase (MAPK) pathway upstream of KRAS and MEK. PTPN11/Shp2 somatic mutations occur frequently in Juvenile myelomonocytic leukaemia (JMML); however, the
Autor:
Jan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, Kristiaan Nackaerts, Marc de Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Steven G. Gray, Luca Ampollini, Joachim G. Aerts, Emanuela Felley-Bosco, Michaela B. Kirschner, Kim Monkhorst, Birgit Weynand, Fatemeh Bavaghar-Zaeimi, Miroslav Samarzija, Roger Llatjos, Stephen P. Finn, Enrico Silini, Jan von der Thüsen, Nesa Marti, Karerina Vervita, Roswitha Kammler, Solange Peters, Rolf A. Stahel, Paul Baas, Isabelle Opitz, Rolf Stahel, Anita Hiltbrunner, Rosita Kammler, Patrick Vagenknecht, Barbara Ruepp, Urania Dafni, Panagiota Zygoura, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Androniki Stavrou, Jan H. Rüschoff, Susanne Dettwiler, Fabiola Prutek, Christiane Mittmann, Bart Vrugt, Martina Friess, Alessandra Matter, Chloé Spichiger-Häusermann, Eric Verbeken, Birgit Weyenand, Liesbet Peeters, Marcello Tiseo, Enrico Maria Silini, Luigi Ventura, Letizia Gnetti, Paolo Carbognani, Fatemeh B. Zaeimi, Sven Seiwerth, Marko Jakopovic, Felipe Cardenal, Susana Lorente, Konstantinos Syrigos, Ioannis Vamvakaris, Paraskevi Boura, Steven Gray, Mutaz Mohammed Nur, Anne-Marie Baird, Martin Barr, Sinead Cuffe, Kathy Gately, Joachim Aerts
Publikováno v:
Modern Pathology, 35(12), 1888-1899. SPRINGERNATURE
Modern Pathology, 35(12), 1888-1899. Nature Publishing Group
Modern Pathology, 35(12), 1888-1899. Nature Publishing Group
Pleural mesothelioma (PM) is an aggressive malignancy with poor prognosis. Although histology and pathologic stage are important prognostic factors, better prognostic biomarkers are needed. The ribosomal protein S6 is a downstream target of the phosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::355b5c339b724ea833e0f7b1c96df40e
https://doi.org/10.1038/s41379-022-01145-0
https://doi.org/10.1038/s41379-022-01145-0
Autor:
Thamir Mahgoub, Kenneth J. O'Byrne, John Crown, Clare Hughes, Frankie A. Holmes, Virginia Espina, Anthony Davies, Marion Le Gal, Alex J Eustace, Lance A. Liotta, Kathy Gately, Norma O'Donovan, Darran P. O'Connor, Max Hasmann, Denis M. Collins, Sinead Toomey, Dalal Alsultan, Jo Ballot, Birgit Bossenmaier, N. Gaynor, Stephen F. Madden, Bryan T. Hennessy, William M. Gallagher
Publikováno v:
Clin Cancer Res
Purpose: Antibody-dependent cell-mediated cytotoxicity (ADCC) is one mechanism of action of the monoclonal antibody (mAb) therapies trastuzumab and pertuzumab. Tyrosine kinase inhibitors (TKIs), like lapatinib, may have added therapeutic value in com